Cardiometabolic Heal
Cardiometabolic Health Congress Hosts 2023 Women's Masterclass in California
29 juin 2023 11h00 HE | Cardiometabolic Health Congress
Boca Raton, FL, June 29, 2023 (GLOBE NEWSWIRE) -- Informed by topics most relevant to cardiometabolic health providers, medical education leader Cardiometabolic Health Congress (CMHC) has announced...
Global Advanced Driver Assistance Systems (ADAS) Market Size/Share Worth USD 81.17 Billion by 2032 at an 18.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
05 juin 2023 16h30 HE | Custom Market Insights
Austin, TX, USA, June 05, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Advanced Driver Assistance Systems (ADAS) Market Size, Trends and Insights By...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
16 mars 2023 08h00 HE | Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Esperion Logo (primary).png
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
19 déc. 2022 16h15 HE | Esperion Therapeutics, Inc.
– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral...
QuisLex Fall Schedule to Feature In-Person and Virtual Events
08 sept. 2022 09h16 HE | QuisLex
Calendar of forums and conferences includes speaking engagements and sponsorships of premier events including SOLID, CLOC, ACC and Consero legal forums NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) --...
Esperion Logo (primary).png
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
26 août 2022 08h16 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for...
Esperion Logo (primary).png
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
03 avr. 2022 12h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American...
ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
17 mai 2021 08h00 HE | Nuwellis, Inc.
EDEN PRAIRIE, Minn., May 17, 2021 (GLOBE NEWSWIRE) -- Data supporting the effectiveness of Aquadex FlexFlow® system in the treatment of acutely decompensated heart failure (ADHF) patients was...
ACC winning recipe
N.C. Pulled Pork Sliders Slam Dunks the Competition in Food Lion ACC Recipe Tournament
17 mars 2021 15h08 HE | Food Lion
SALISBURY, N.C., March 17, 2021 (GLOBE NEWSWIRE) -- N.C. Pulled Pork Sliders crushed the field in the inaugural Food Lion Atlantic Coast Conference Recipe Tournament, which assigned classic game day...
ETRM Group Logo.png
Empire Technologies Risk Management Group Selected as Accredited, Recommended Service Provider for the ACC’s New Data Steward Program
06 janv. 2021 09h00 HE | ETRM Group
WASHINGTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Empire Technologies Risk Management Group (ETRM Group), the experts on data security, announces that it has been selected by the Association of...